VLA 0.00% $1.75 viralytics limited

Incredulous, page-33

  1. 89 Posts.
    lightbulb Created with Sketch. 12
    The shareholders have been sold short..
    Why did'nt Viralytics wait to release the clinical data from the keynote trail before
    doing an agreement with merck.
    I expect the data to be released to be outstanding and that would have given viralytics a much
    better bargaining position.
    whereby cavatek will have multiple uses in combination.A very attractive proposition to big pharma
    with pd1 inhibitors.
    The acquisition agreement will be finalised by the end of june.The keynote trail data is to released
    2q2018 so the shareholders will have prior knowledge before deciding which way to vote.
    Is it possible now that viralytics will delay releasing the keynote trial data until after the deadline for the acquistion.
    If big pharma get access to outstanding keynote trial data before the vote then maybe a bid from another party.
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.